2566: Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. - Summary | Jitta

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.

HKG:2566

Price
HK$5.78
Loss Chance
44.1%
5.59JITTA SCORE
3.24%Over Jitta Line
Jitta Ranking
30 / 241
239 / 2,586
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (60)
Recent Business Performance (85)
Financial Strength (79)
Return to Shareholders (20)
Competitive Advantage (46)
Jitta Signs
Debt LevelLow Long Term Debt
Interest Coverage RatioVery Good
Recent IPOLess than 3 years
Operating MarginInconsistent
Key Stats
Jitta Score
Jitta Line
5.59
3.24%
3.08
957.99%
3.80
412.99%
Biotechnology
7.67
80.07%
5.27
146.20%
4.91
1.06%
COMPANY DESCRIPTION
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, manufacturing, and commercialization of biopharmaceutical products and medical devices in Mainland China and internationally. The company offers Guyoudao, a bone repair material; Jilifen, a human granulocyte colony stimulating factor injection; Jijufen, a human interleukin-11 injection; Jiouting, a palonosetron hydrochloride injection; Jifuwei, a fulvestrant injection; Jitansu, a fosaprepitant dimeglumine injection; and Jixinfen, PEG-G–CSF injection. It also provides Jilixin avatrombopag maleate tablets; Jipailin, a low molecular weight heparin sodium injection; and Yinuojia, an enoxaparin sodium injection. The company was formerly known as Hangzhou Jiuyuan Gene Engineering Co., Ltd. and changed its name to Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. in April 2025. Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. was incorporated in 1993 and is headquartered in Hangzhou, China.